Skip to content

Study · Observational study · n = 174 · 2010

7 results

Exenatide therapy in insulin-treated type 2 diabetes and obesity.

Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM

QJM : monthly journal of the Association of Physicians12 Jul 2010Cited by 46 (Europe PMC)

PMID20624837 (opens in a new tab)DOI10.1093/qjmed/hcq112 (opens in a new tab)PepBankPUB-20624837
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studySafety outcome

    In insulin-treated patients with type 2 diabetes and obesity, fourteen discontinued exenatide before 3 months because of side effects.

    In plain wordsIn insulin-treated patients with diabetes and obesity, fourteen discontinued exenatide before 3 months because of side effects.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableEarly discontinuation due to side effects
    Study

    n = 174

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · before 3 monthsAs given in this study (human).

    Measurements

    Early discontinuation due to side effects
    14 patients
    before 3 months of initiation

    Source sentences

    Summary
    Fourteen patients discontinued exenatide before 3 months of initiation, because of side effects, and were excluded.
    2 context sentences
    Summary · context
    This prospective study included 174 consecutive patients with insulin-treated type 2 diabetes and obesity initiated on exenatide in our out-patient, between October 2007 and November 2008.
    Summary · context
    Data were analysed on remaining 160 people all of whom completed 6 months and 57 completed 12 months treatment.
  2. 02HumanObservational studyEfficacy outcome

    In insulin-treated patients with type 2 diabetes and obesity, weight loss during exenatide treatment averaged 10.7 kg at 6 months.

    In plain wordsIn insulin-treated patients with diabetes and obesity, weight loss during exenatide treatment averaged 10.7 kg at 6 months.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight loss at 6 months
    Study

    n = 160

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Mean weight loss
    10.7 kg
    6 months
    Weight loss dispersion
    5.7 kg
    reported +/- at 6 months

    Source sentences

    Summary
    Mean weight loss was 10.7 +/- 5.7 kg and 12.8 +/- 7.5 kg (P < 0.001) at 6 and 12 months.
    2 context sentences
    Summary · context
    This prospective study included 174 consecutive patients with insulin-treated type 2 diabetes and obesity initiated on exenatide in our out-patient, between October 2007 and November 2008.
    Summary · context
    Data were analysed on remaining 160 people all of whom completed 6 months and 57 completed 12 months treatment.
  3. 03HumanObservational studyEfficacy outcome

    In insulin-treated patients with type 2 diabetes and obesity, mean insulin dose fell to 51 U/day during exenatide treatment at 6 months.

    In plain wordsIn insulin-treated patients with diabetes and obesity, mean insulin dose fell to 51 U/day during exenatide treatment at 6 months.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulin dose at 6 months
    Study

    n = 160

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Insulin dose
    144 U/day
    baseline
    Insulin dose dispersion
    90 U/day
    reported +/- at baseline
    Insulin dose
    51 U/day
    6 months
    Insulin dose dispersion
    55 U/day
    reported +/- at 6 months

    Source sentences

    Summary
    Insulin doses dropped significantly (mean 144 +/- 90 U/day at baseline to 51 +/- 55 U/day and 55 +/- 53 U/day at 6 and 12 months).
    2 context sentences
    Summary · context
    This prospective study included 174 consecutive patients with insulin-treated type 2 diabetes and obesity initiated on exenatide in our out-patient, between October 2007 and November 2008.
    Summary · context
    Data were analysed on remaining 160 people all of whom completed 6 months and 57 completed 12 months treatment.
  4. 04HumanObservational studyEfficacy outcome

    In insulin-treated patients with type 2 diabetes and obesity, weight loss during exenatide treatment averaged 12.8 kg at 12 months.

    In plain wordsIn insulin-treated patients with diabetes and obesity, weight loss during exenatide treatment averaged 12.8 kg at 12 months.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight loss at 12 months
    Study

    n = 57

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Mean weight loss
    12.8 kg
    12 months
    Weight loss dispersion
    7.5 kg
    reported +/- at 12 months

    Source sentences

    Summary
    Mean weight loss was 10.7 +/- 5.7 kg and 12.8 +/- 7.5 kg (P < 0.001) at 6 and 12 months.
    2 context sentences
    Summary · context
    This prospective study included 174 consecutive patients with insulin-treated type 2 diabetes and obesity initiated on exenatide in our out-patient, between October 2007 and November 2008.
    Summary · context
    Data were analysed on remaining 160 people all of whom completed 6 months and 57 completed 12 months treatment.
  5. 05HumanObservational studyEfficacy outcome

    In insulin-treated patients with type 2 diabetes and obesity, mean insulin dose fell to 55 U/day during exenatide treatment at 12 months.

    In plain wordsIn insulin-treated patients with diabetes and obesity, mean insulin dose fell to 55 U/day during exenatide treatment at 12 months.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulin dose at 12 months
    Study

    n = 57

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Insulin dose
    144 U/day
    baseline
    Insulin dose dispersion
    90 U/day
    reported +/- at baseline
    Insulin dose
    55 U/day
    12 months
    Insulin dose dispersion
    53 U/day
    reported +/- at 12 months

    Source sentences

    Summary
    Insulin doses dropped significantly (mean 144 +/- 90 U/day at baseline to 51 +/- 55 U/day and 55 +/- 53 U/day at 6 and 12 months).
    2 context sentences
    Summary · context
    This prospective study included 174 consecutive patients with insulin-treated type 2 diabetes and obesity initiated on exenatide in our out-patient, between October 2007 and November 2008.
    Summary · context
    Data were analysed on remaining 160 people all of whom completed 6 months and 57 completed 12 months treatment.
  6. 06HumanObservational studyEfficacy outcome

    In insulin-treated patients with type 2 diabetes and obesity, 25% were off insulin at 3 months of exenatide treatment.

    In plain wordsIn insulin-treated patients with diabetes and obesity, 25% were off insulin at 3 months of exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableInsulin cessation
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Measurements

    Stopped insulin
    25%
    3 months

    Source sentences

    Summary
    At 3 months, 25% came off insulin.
    2 context sentences
    Summary · context
    This prospective study included 174 consecutive patients with insulin-treated type 2 diabetes and obesity initiated on exenatide in our out-patient, between October 2007 and November 2008.
    Summary · context
    Data were analysed on remaining 160 people all of whom completed 6 months and 57 completed 12 months treatment.
  7. 07HumanObservational studyEfficacy outcome

    In insulin-treated patients with type 2 diabetes and obesity, HbA1c changed little during exenatide treatment, without a stated significance test.

    In plain wordsIn insulin-treated patients with diabetes and obesity, HbA1c changed little during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedHbA1c change
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was little change in HbA1c.
    2 context sentences
    Summary · context
    This prospective study included 174 consecutive patients with insulin-treated type 2 diabetes and obesity initiated on exenatide in our out-patient, between October 2007 and November 2008.
    Summary · context
    Data were analysed on remaining 160 people all of whom completed 6 months and 57 completed 12 months treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.